Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Official Title

An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP)

Keywords

Erythropoietic Protoporphyria, EPP, DISC-1459, porphyria, RO4917838

Eligibility

Locations

  • UCSF
    San Francisco California 94117 United States
  • Fred Hutchinson Cancer Center
    Seattle Washington 98109 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Disc Medicine, Inc
ID
NCT05883748
Phase
Phase 2/3 Erythropoietic Protoporphyria Research Study
Study Type
Interventional
Participants
Expecting 200 study participants
Last Updated